Testosterone supplements may help heart failure patients
April 17, 2012
- Testosterone supplements helped stable heart failure patients with moderate to severe disease breathe better and exercise more, according to a review of four previous studies.
- None of the male patients developed signs of prostate disease and there was no increase in cardiovascular events.
- However, large clinical trials are needed before being able to translate these findings to clinical practice.
EMBARGOED UNTIL 3 pm CT/4 pm ET, Tuesday, April 17
DALLAS, April 17, 2012 – Testosterone supplements helped heart failure
patients breathe better and exercise more, according to research in Circulation Heart Failure
, an American Heart Association journal.
Researchers analyzed four randomized clinical trials of patients with moderate to severe chronic heart failure. Patients were given commercial testosterone supplements by injection, patch or gel.
Based on the analysis of these studies, those who received supplemental testosterone scored 50 percent better in a six-minute walking test than those receiving placebo.
Also, in two of the studies, the severity of heart failure as measured by the New York Heart Association classification
system improved one to two grades in 35 percent of treated patients compared to 9.8 percent of those who didn’t receive the supplements. Researchers noted gains in muscle and skeletal endurance that appeared quickly and lasted for a least one year.
“The improvement in exercise capacity was consistent across all of the studies,” said Justin A. Ezekowitz, M.D., M.Sc., study author and assistant professor and director of the Heart Function Clinic at the University of Alberta in Edmonton, Canada. “Compared to patients in placebo groups, the differences were striking.”
If the findings are confirmed in larger clinical trials, testosterone therapy could be one of the first heart failure therapies targeting the peripheral (skeletal) muscle rather than the cardiac muscle, he said.
The studies included 198 patients, 84 percent men, averaging 67 years of age. One study exclusively in women who were taking lower doses of testosterone than men, found similar improvements.
No significant adverse events were reported, including treatment- or exercise-related cardiovascular events, and there was no increase in prostate cancer or abnormal prostate health parameters in the men.
While the results are encouraging, larger studies are needed as well as studies of the various testosterone delivery methods, Ezekowitz said. “We don’t want patients and their loved ones rushing to buy testosterone supplements online, or physicians to misinterpret the findings. First the results need to be corroborated in large clinical trials.”
Co-authors are Jeffrey Bakal, Ph.D.; Paul Armstrong, M.D.; Mustafa Toma, M.D.; Erin Coglianese, M.D.; Venketesan Vidi, M.D.; and Samip Vasaiwala, M.D. Author disclosures are on the manuscript.
The study was partly funded by New Investigator Awards from the Canadian Institutes of Health Research and Alberta Innovates – Health Solutions.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding
NR12 – 1060 (Circ Heart Failure/Ezekowitz)
Additional resources are available in the right column.
For Media Inquiries: (214) 706-1173
For other information, contact:
For Public Inquiries: (800) AHA-USA1 (242-8721)